Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Targeting the oncogene and kinome chaperone CDC37.

Gray PJ Jr, Prince T, Cheng J, Stevenson MA, Calderwood SK.

Nat Rev Cancer. 2008 Jul;8(7):491-5. doi: 10.1038/nrc2420. Epub 2008 May 30. Review.

2.

Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.

Gray PJ Jr, Stevenson MA, Calderwood SK.

Cancer Res. 2007 Dec 15;67(24):11942-50.

3.
4.

Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion.

El Hamidieh A, Grammatikakis N, Patsavoudi E.

PLoS One. 2012;7(8):e42722. doi: 10.1371/journal.pone.0042722. Epub 2012 Aug 17.

5.

Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.

Smith JR, Workman P.

Cell Cycle. 2009 Feb 1;8(3):362-72. Epub 2009 Feb 2.

PMID:
19177013
6.

Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.

Mariño-Enríquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA.

Oncogene. 2014 Apr 3;33(14):1872-6. doi: 10.1038/onc.2013.127. Epub 2013 Apr 15.

7.

Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.

Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):498-503. doi: 10.1016/j.bbrc.2010.12.010. Epub 2010 Dec 6.

PMID:
21144839
8.

Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia.

Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW.

Oncogene. 2000 Apr 27;19(18):2186-93.

9.

Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.

Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD.

Mol Cancer. 2011 Aug 29;10:104. doi: 10.1186/1476-4598-10-104.

10.

A client-binding site of Cdc37.

Terasawa K, Minami Y.

FEBS J. 2005 Sep;272(18):4684-90.

11.

Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.

Stepanova L, Leng X, Parker SB, Harper JW.

Genes Dev. 1996 Jun 15;10(12):1491-502.

12.

Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.

Wang Z, Wei W, Sun CK, Chua MS, So S.

Liver Int. 2015 Apr;35(4):1403-15. doi: 10.1111/liv.12651. Epub 2014 Aug 25.

PMID:
25098386
13.

Characterization of celastrol to inhibit hsp90 and cdc37 interaction.

Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D.

J Biol Chem. 2009 Dec 18;284(51):35381-9. doi: 10.1074/jbc.M109.051532.

14.

Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

Pearl LH.

Curr Opin Genet Dev. 2005 Feb;15(1):55-61. Review.

PMID:
15661534
15.

Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.

Eckl JM, Rutz DA, Haslbeck V, Zierer BK, Reinstein J, Richter K.

J Biol Chem. 2013 May 31;288(22):16032-42. doi: 10.1074/jbc.M112.439257. Epub 2013 Apr 8.

16.

Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.

He J, Niu X, Hu C, Zhang H, Guo Y, Ge Y, Wang G, Jiang Y.

Protein Expr Purif. 2013 Nov;92(1):119-27. doi: 10.1016/j.pep.2013.09.007. Epub 2013 Sep 19.

PMID:
24056254
17.

Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery.

Miyata Y.

Cell Mol Life Sci. 2009 Jun;66(11-12):1840-9. doi: 10.1007/s00018-009-9152-0. Review.

PMID:
19387550
18.

Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.

Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM, Panaretou B, Neckers L, Clarke PA, Workman P, Piper PW, Prodromou C, Pearl LH.

Mol Cell. 2008 Sep 26;31(6):886-95. doi: 10.1016/j.molcel.2008.07.021.

19.

The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.

Jin Y, Zhen Y, Haugsten EM, Wiedlocha A.

Cell Signal. 2011 Nov;23(11):1758-66. doi: 10.1016/j.cellsig.2011.06.010. Epub 2011 Jun 30.

PMID:
21745565
20.

The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy.

Sreeramulu S, Jonker HR, Langer T, Richter C, Lancaster CR, Schwalbe H.

J Biol Chem. 2009 Feb 6;284(6):3885-96. doi: 10.1074/jbc.M806715200. Epub 2008 Dec 10.

Supplemental Content

Support Center